{"title":"类风湿关节炎患者肺间质性疾病的临床指标及肺超声检查","authors":"Schneeberger Emilce Edith, Perandones Miguel, Rosemffet Marcos Gabriel, Otaola María, Cazenave Tomás, Barbich Tatiana, Carrizo Abarza Virginia, Balcazar Jonathan, Citera Gustavo","doi":"10.1007/s10067-025-07510-z","DOIUrl":null,"url":null,"abstract":"<p><p>The best screening way to detect interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is still debated.</p><p><strong>Objectives: </strong>To evaluate the performance of scores to identify patients with ILD in patients with RA.</p><p><strong>Methods: </strong>Cross-sectional study, adult outpatients with RA were included and those with any disease that can affect lung ultrasonography (LUS) evaluation were excluded. Sociodemographic, clinical, and therapeutic variables were recorded. All patients underwent chest x-rays, pulmonary function tests (PFT), LUS, and high-resolution chest tomography (HRCT). Univariate and multivariate analyses and ROC curves.</p><p><strong>Results: </strong>107 patients with RA, median age of 62 years (IQR 36-84), 82.2% female, and median disease duration 14 years (IQR 1-42). A total of 30 patients (29.5%) had ILD by HRCT. The classic cutoff value of ≥ 5 B lines in the LUS (ILD by HRCT as the gold standard) showed an AUC of 0.86 (95% CI 0.78-0.94), Se 87.1%, and Sp 74.3% for the detection of ILD. A clinical score made up of 5 variables to identify the presence of ILD, based on the strength of association in the multivariate analysis: male sex, crackles, age ≥ 60 years, RF + , anti-CCP + . Range 0-11, cutoff value ≥ 5.5, AUC 0.80 (95% CI 0.70-0.89), Se 75%, and Sp 71%. When we added the LUS variable to this score: lines B ≥ 5, the range was 0-15, a cutoff value ≥ 7.5, AUC 0.88 (95% CI 0.81-0.94), Se improved to 84.4%, and Sp 75%. However, this last score did not exceed the performance of isolated LUS.</p><p><strong>Conclusions: </strong>LUS is a good tool for detecting ILD in patients with RA. Key Points • Interstitial lung disease (ILD) is an extra-musculoskeletal manifestation with high morbidity and mortality in patients with rheumatoid arthritis (RA). Early detection could improve the prognosis of these patients. • High-resolution chest tomography (HRCT) is the gold standard for ILD diagnosis, but high radiation and limited access hinder its use. • Lung ultrasound (LUS) is an excellent tool for detecting ILD in RA patients and performs better than clinical scores. • LUS provides a method of screening for ILD in patients with RA in a simple, cheap, safe, and effective way.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical variables and lung ultrasonography for the screening of interstitial lung disease in patients with rheumatoid arthritis.\",\"authors\":\"Schneeberger Emilce Edith, Perandones Miguel, Rosemffet Marcos Gabriel, Otaola María, Cazenave Tomás, Barbich Tatiana, Carrizo Abarza Virginia, Balcazar Jonathan, Citera Gustavo\",\"doi\":\"10.1007/s10067-025-07510-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The best screening way to detect interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is still debated.</p><p><strong>Objectives: </strong>To evaluate the performance of scores to identify patients with ILD in patients with RA.</p><p><strong>Methods: </strong>Cross-sectional study, adult outpatients with RA were included and those with any disease that can affect lung ultrasonography (LUS) evaluation were excluded. Sociodemographic, clinical, and therapeutic variables were recorded. All patients underwent chest x-rays, pulmonary function tests (PFT), LUS, and high-resolution chest tomography (HRCT). Univariate and multivariate analyses and ROC curves.</p><p><strong>Results: </strong>107 patients with RA, median age of 62 years (IQR 36-84), 82.2% female, and median disease duration 14 years (IQR 1-42). A total of 30 patients (29.5%) had ILD by HRCT. The classic cutoff value of ≥ 5 B lines in the LUS (ILD by HRCT as the gold standard) showed an AUC of 0.86 (95% CI 0.78-0.94), Se 87.1%, and Sp 74.3% for the detection of ILD. A clinical score made up of 5 variables to identify the presence of ILD, based on the strength of association in the multivariate analysis: male sex, crackles, age ≥ 60 years, RF + , anti-CCP + . Range 0-11, cutoff value ≥ 5.5, AUC 0.80 (95% CI 0.70-0.89), Se 75%, and Sp 71%. When we added the LUS variable to this score: lines B ≥ 5, the range was 0-15, a cutoff value ≥ 7.5, AUC 0.88 (95% CI 0.81-0.94), Se improved to 84.4%, and Sp 75%. However, this last score did not exceed the performance of isolated LUS.</p><p><strong>Conclusions: </strong>LUS is a good tool for detecting ILD in patients with RA. Key Points • Interstitial lung disease (ILD) is an extra-musculoskeletal manifestation with high morbidity and mortality in patients with rheumatoid arthritis (RA). Early detection could improve the prognosis of these patients. • High-resolution chest tomography (HRCT) is the gold standard for ILD diagnosis, but high radiation and limited access hinder its use. • Lung ultrasound (LUS) is an excellent tool for detecting ILD in RA patients and performs better than clinical scores. • LUS provides a method of screening for ILD in patients with RA in a simple, cheap, safe, and effective way.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-025-07510-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07510-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
类风湿关节炎(RA)患者间质性肺疾病(ILD)的最佳筛查方法仍存在争议。目的:评价评分在RA患者中识别ILD患者的表现。方法:横断面研究,纳入成年RA门诊患者,排除任何影响肺超声(LUS)评价的疾病。记录社会人口学、临床和治疗变量。所有患者均接受胸片、肺功能检查(PFT)、LUS和高分辨率胸部断层扫描(HRCT)检查。单因素和多因素分析及ROC曲线。结果:RA患者107例,中位年龄62岁(IQR 36-84), 82.2%为女性,中位病程14年(IQR 1-42)。HRCT显示30例(29.5%)患者有ILD。LUS中≥5条B线的经典截断值(HRCT为金标准)显示,检测ILD的AUC为0.86 (95% CI 0.78-0.94), Se为87.1%,Sp为74.3%。一个由5个变量组成的临床评分,根据多变量分析中的关联强度来确定ILD的存在:男性、裂纹、年龄≥60岁、RF +、anti-CCP +。范围0-11,临界值≥5.5,AUC 0.80 (95% CI 0.70-0.89), Se 75%, Sp 71%。当我们将LUS变量加入该评分时:B线≥5,范围为0-15,临界值≥7.5,AUC为0.88 (95% CI 0.81-0.94), Se提高到84.4%,Sp提高到75%。然而,最后一个分数并没有超过孤立LUS的性能。结论:LUS是检测RA患者ILD的良好工具。•间质性肺疾病(ILD)是类风湿性关节炎(RA)患者的一种高发病率和死亡率的肌肉骨骼外表现。早期发现可以改善这些患者的预后。•高分辨率胸部断层扫描(HRCT)是ILD诊断的金标准,但高辐射和有限的通道阻碍了它的使用。•肺超声(LUS)是检测类风湿性关节炎患者ILD的极好工具,其表现优于临床评分。•LUS为类风湿性关节炎患者提供了一种简单、廉价、安全、有效的ILD筛查方法。
Clinical variables and lung ultrasonography for the screening of interstitial lung disease in patients with rheumatoid arthritis.
The best screening way to detect interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) is still debated.
Objectives: To evaluate the performance of scores to identify patients with ILD in patients with RA.
Methods: Cross-sectional study, adult outpatients with RA were included and those with any disease that can affect lung ultrasonography (LUS) evaluation were excluded. Sociodemographic, clinical, and therapeutic variables were recorded. All patients underwent chest x-rays, pulmonary function tests (PFT), LUS, and high-resolution chest tomography (HRCT). Univariate and multivariate analyses and ROC curves.
Results: 107 patients with RA, median age of 62 years (IQR 36-84), 82.2% female, and median disease duration 14 years (IQR 1-42). A total of 30 patients (29.5%) had ILD by HRCT. The classic cutoff value of ≥ 5 B lines in the LUS (ILD by HRCT as the gold standard) showed an AUC of 0.86 (95% CI 0.78-0.94), Se 87.1%, and Sp 74.3% for the detection of ILD. A clinical score made up of 5 variables to identify the presence of ILD, based on the strength of association in the multivariate analysis: male sex, crackles, age ≥ 60 years, RF + , anti-CCP + . Range 0-11, cutoff value ≥ 5.5, AUC 0.80 (95% CI 0.70-0.89), Se 75%, and Sp 71%. When we added the LUS variable to this score: lines B ≥ 5, the range was 0-15, a cutoff value ≥ 7.5, AUC 0.88 (95% CI 0.81-0.94), Se improved to 84.4%, and Sp 75%. However, this last score did not exceed the performance of isolated LUS.
Conclusions: LUS is a good tool for detecting ILD in patients with RA. Key Points • Interstitial lung disease (ILD) is an extra-musculoskeletal manifestation with high morbidity and mortality in patients with rheumatoid arthritis (RA). Early detection could improve the prognosis of these patients. • High-resolution chest tomography (HRCT) is the gold standard for ILD diagnosis, but high radiation and limited access hinder its use. • Lung ultrasound (LUS) is an excellent tool for detecting ILD in RA patients and performs better than clinical scores. • LUS provides a method of screening for ILD in patients with RA in a simple, cheap, safe, and effective way.
期刊介绍:
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.